Skip to content

Talphera, Inc. TLPH Additional Paid-In Capital

Additional Paid-In Capital at other companies

Baxter International logo
Baxter InternationalBAX
$6.21B-1.5%
AMP
Amphastar PharmaceuticalsAMPH
$543.82M+6.8%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$1.59B+4.6%
Royalty Pharma logo
Royalty PharmaRPRX
$4.38B+4.1%
PTH
Pelthos Therapeutics Inc.PTHS
$106.95M+456%
XOMA Corporation logo
XOMA CorporationXOMA
$1.31B-0.7%

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+516%
P/S53,456.6×+53,135×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Reported directly by Talphera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Talphera, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s additional paid-in capital?
Talphera, Inc. (TLPH) reported additional paid-in capital of $492.5M in Q1 2026.
How has Talphera, Inc.'s additional paid-in capital changed year-over-year?
Talphera, Inc.'s additional paid-in capital increased by 5.8% year-over-year, from $465.41M to $492.5M.
What is the long-term trend for Talphera, Inc.'s additional paid-in capital?
Over 5 years (2020 to 2025), Talphera, Inc.'s additional paid-in capital has grown at a 5.0% compound annual growth rate (CAGR), from $382.64M to $488.51M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.